Figure 2.

OMS treatment promotes antimicrobial responses against Mabc infection in immunocompetent and immunodeficient mouse models.(a, c) C3HeB/FeJ mice were infected intranasally with Mabc (1 × 10⁴ CFU), with or without OMS treatment (five times a week; 10 mg/kg i.P.), and monitored at 14 dpi. Schematic diagram of the immunocompetent mouse model design (a) and CFU assay of lung tissues (c). (b, d) BALB/C mice were treated with or without dexamethasone (daily s.c. 5 mg/kg) over 2 weeks. After treatment, the mice were infected intranasally with Mabc (1 × 10³ CFU), treated with or without OMS (five times a week; 10 mg/kg i.P.), and monitored at 21 dpi. Schematic diagram of the immunodeficient mouse model (b) and CFU assay in the lung tissues (d). Statistical significance was assessed using the two-tailed Student’s t-test (c) and one-way ANOVA with Tukey’s multiple comparison test (d). Data are means ± SEM of three independent experiments. *** p < 0.001. dpi, days post infection; CFU, colony forming units; OMS, ohmyungsamycin A; DXA, dexamethasone.